Creative Graphic

- The company is largely done with major Capex and does not currently plan any significant additional capital expenditure. - Working capital requirements are expected to increase due to business expansion and extended credit periods to large pharma clients. - The management is actively discussing and arranging working capital financing, primarily through debt. - No plans for further equity dilution at present; working capital needs to be met through debt or other financing. - Off-balance sheet financing options like invoice/bill discounting are being explored to fund receivables. - Interest costs from such financing will be factored into pricing, implying the company or customers bear it. - A materialization or breakthrough in bill discounting is expected within the next month. - For at least the next 6 months, existing financing arrangements are considered sufficient. Further funding decisions will depend on working capital consumption and business growth.

- The company is largely done with major Capex; no large Capex planned currently. - Minor investments may occur for small capacity changes or material-related extensions. - Recent expansions include new plants in Oman and Bangalore for flexography business. - Pharmaceutical packaging business is expanding with 3 new lines: tandem line, PVC/PVDC line, and Alu-Alu capacity expansion. - The Wahren unit is undergoing capacity expansion from 8,000 tons to 20,000 tons; the new machine is in the last commissioning leg. - They acquired high-value machines (PVC/PVDC and tandem) at discounted prices through NCLT. - The company is focused on executing existing expansion plans to reach 1000+ crores turnover in the next few years. - Working capital requirements to be funded mainly via working capital debt; no immediate plan for equity dilution.

- The company targets to achieve a revenue of ₹1000 crore within the next couple of years, aiming to double revenue annually. - Capacity expansions include increasing Alu-Alu capacity from 8,000 to 20,000 tons, targeting over 50% utilization in FY27. - PVDC and tandem line capacities are expected to contribute, with PVDC initially at 30-40% utilization in FY27. - Order books currently exceed supply, indicating strong demand and supply-side constraints. - New capacities and product lines (PVDC, tandem line) are expected to drive growth and diversify revenue streams. - The company anticipates robust growth in FY27, leveraging overspill orders and new client acquisitions. - Expects revenue potential of ₹700-750 crore from Wahren (Alu-Alu) and ₹200-250 crore from PVDC at full capacity. - Expansion largely funded; working capital needs to be managed with debt and no immediate equity dilution planned.

- The company aims to achieve a revenue of ₹1,000 crore over the next couple of years, targeting to double revenue annually. - Profit growth has been strong, with a 68% CAGR and achieving ₹20+ crore PAT in the last financial year. - For FY27 and FY28, the management expects: - Alu-Alu pharmaceutical packaging EBITDA margins in low teens (11-13%). - Flexography business margins to remain in high teens to low 20s. - Despite recent pressure from aluminum price rises and expansion costs, long-term profit margins are expected to be stable or improve. - Capacity expansions (including new machines and plants) are anticipated to drive volume growth and better cost absorption, supporting future margin improvement. - Near-term PAT may face temporary pressure due to expansions, but growth momentum and margin profile are expected to sustain or improve over time. - Earnings per share (EPS) is likely to grow aligned with revenue growth and operational efficiencies post-expansions.

- The company carries 15-20 days of overflow orders, which are currently being rolled over into the next month due to capacity constraints. - With the new capacity installation expected to start soon, the company anticipates being able to fulfill all client orders within the same month. - There is constant pressure on production and consistent challenges due to capacity, but the expansion will help reduce fixed costs and improve margins. - The order book consistently exceeds supply capacity, causing orders to spill into subsequent months, indicating strong demand. - New client acquisitions are ongoing, and there is no expected difficulty in absorbing the increased capacity and fulfilling orders. - Overall, the company expects order fulfillment to improve significantly post capacity expansion, benefiting margin profiles and operational efficiency.